Safety and Efficacy of Autologous CD34+ Hematopoietic Progenitor Cells Transduced with an Anti-Tat Ribozyme in a Multi-Center, Randomized, Placebo-Controlled, Phase II Gene Therapy Trial for the Human Immunodeficiency Virus

Gene transfer has potential as a once-only treatment that reduces viral load, preserves the immune system, and avoids lifetime highly active antiretroviral therapy. This study, the first randomized, double-blind, placebo-controlled, phase II cell-delivered gene transfer clinical trial, was conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitsuyasu, Ronald T, Merigan, Thomas C, Carr, Andrew, Zack, Jerome A, Winters, Mark A, Workman, Cassy, Bloch, Mark, Lalezari, Jacob, Becker, Stephen, Thornton, Lorna, Akil, Bisher, Khanlou, Homayoon, Finlayson, Robert, McFarlane, Robert, Smith, Don E, Garsia, Roger, Ma, David, Law, Matthew, Murray, John M., von Kalle, Christof, Ely, Julie A, Patino, Sharon M, Knop, Alison E, Wong, Philip, Todd, Alison V, Haughton, Margaret, Fuery, Caroline, Macpherson, Janet L, Symonds, Geoff P, Evans, Louise A, Pond, Susan M, Cooper, David A
Formato: Texto
Lenguaje:English
Publicado: 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768566/
https://www.ncbi.nlm.nih.gov/pubmed/19219022
http://dx.doi.org/10.1038/nm.1932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768566/
https://www.ncbi.nlm.nih.gov/pubmed/19219022
http://dx.doi.org/10.1038/nm.1932

Ejemplares similares